QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial
LON:MXCT

MaxCyte (MXCT) Share Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)
Free MXCT Stock Alerts
GBX 310
-5.00 (-1.59%)
(As of 03:29 PM ET)
Compare
Today's Range
310
▼
311.13
50-Day Range
310.10
▼
385
52-Week Range
180
▼
435
Volume
273 shs
Average Volume
33,620 shs
Market Capitalization
£322.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlinesInsider Trades
MXCT stock logo

About MaxCyte Stock (LON:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

April 3, 2024 | insidertrades.com
MaxCyte, Inc. (LON:MXCT) Insider Sells £22,050 in Stock
April 4, 2024 | finance.yahoo.com
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 14, 2024 | finance.yahoo.com
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
March 13, 2024 | finance.yahoo.com
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
March 12, 2024 | finance.yahoo.com
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
March 11, 2024 | markets.businessinsider.com
MaxCyte earnings: here's what Wall Street expects
March 11, 2024 | benzinga.com
MaxCyte Earnings Preview
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 27, 2024 | msn.com
MaxCyte Inc Announces Cenk Sumen’s Transition and Severance Terms
January 9, 2024 | finanznachrichten.de
MaxCyte, Inc.: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 8, 2024 | msn.com
MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M
January 8, 2024 | finance.yahoo.com
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 3, 2024 | msn.com
MaxCyte and Lion TCR join hands for Lion TCR's global expansion
December 12, 2023 | bizjournals.com
Longtime MaxCyte CEO Doug Doerfler to retire; Maher Masoud tapped as successor
December 2, 2023 | finance.yahoo.com
Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)
November 27, 2023 | seekingalpha.com
MaxCyte May Benefit From Potential Gene Therapy Approval
November 16, 2023 | finance.yahoo.com
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
November 15, 2023 | finance.yahoo.com
MaxCyte, Inc. (LON:MXCT) Analysts Just Cut Their EPS Forecasts Substantially
November 9, 2023 | finance.yahoo.com
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript
November 8, 2023 | finance.yahoo.com
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
November 6, 2023 | finance.yahoo.com
MaxCyte to Participate in Two Upcoming Investor Conferences
October 23, 2023 | finance.yahoo.com
One MaxCyte Insider Raised Stake By 400% In Previous Year
October 7, 2023 | finance.yahoo.com
Need To Know: The Consensus Just Cut Its MaxCyte, Inc. (LON:MXCT) Estimates For 2023
October 4, 2023 | ca.investing.com
After-hours movers: Clorox falls on Q1 warning, BlackBerry up on split-off plans
October 4, 2023 | finance.yahoo.com
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
September 19, 2023 | finance.yahoo.com
MaxCyte, Inc. (MXCT) Stock Historical Prices & Data - Yahoo Finance
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
LON:MXCT
CUSIP
N/A
CIK
N/A
Web
www.maxcyte.com
Phone
+1-301-9441700
Fax
N/A
Employees
143
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-37,920,000.00
Net Margins
-91.85%
Pretax Margin
N/A
Return on Equity
-15.60%
Return on Assets
-10.88%

Debt

Debt-to-Equity Ratio
8.07
Current Ratio
10.65
Quick Ratio
14.38

Sales & Book Value

Annual Sales
£41.29 million
Price / Sales
7.82
Cash Flow
GBX 157.20 per share
Price / Cash Flow
1.97
Book Value
GBX 223 per share
Price / Book
1.39

Miscellaneous

Outstanding Shares
104,130,000
Free Float
N/A
Market Cap
£322.80 million
Optionable
Not Optionable
Beta
1.04
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Maher Masoud (Age 48)
    President, CEO, Secretary & Director
    Comp: $484.7k
  • Mr. Douglas Arthur Doerfler (Age 68)
    Founder
    Comp: $950.01k
  • Mr. Douglas J. Swirsky CFA (Age 55)
    CPA, Chief Financial Officer
  • Mr. Jay Gelfman
    Senior Vice President of Operations
  • Mr. Ronald Evan Holtz CPA (Age 66)
    Ph.D., Executive Vice President of Administration
    Comp: $514.26k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. David Sandoval
    Senior Vice President & General Counsel
  • Mr. Thomas Michael Ross (Age 63)
    Executive Vice President of Global Sales
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Ms. Jill Mayer
    Senior Vice President of Human Resources

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed in 2024?

MaxCyte's stock was trading at GBX 352.50 on January 1st, 2024. Since then, MXCT stock has decreased by 12.1% and is now trading at GBX 310.
View the best growth stocks for 2024 here.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

How do I buy shares of MaxCyte?

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:MXCT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
AI healthcare stock poised for 36,996% growth?
Behind the Markets